Resolutions from Affibody’s Extraordinary General Meeting (EGM)
August 20, 2013
Stockholm, Sweden, August 20, 2013. The Affibody Holding AB’s (publ) (Affibody) EGM convened earlier today in Stockholm and voted in favor of the resolutions proposed at the meeting, including:
Directed new issue of shares
It was resolved to increase the share capital by SEK 2.25 through the issue of nine (9) shares. The right to subscribe for new shares shall, with deviation from the shareholders’ preferential rights, apply to David Bejker. The reason for the deviation from the shareholders’ preferential rights was to obtain a total number of shares in the company that is evenly divisible by 20 in the impending consolidation of shares. Subscription of shares shall be made by subscription on the subscription list no later than 31 August 2013. The new shares were issued at a price of SEK 0.25 per share. Payment for subscribed shares must be made by 31 August 2013 by cash payment.
Adoption of new Articles of Association
It was resolved to adopt new articles of association according to which § § 1, 2, 4 and 5, gets the following wording:
§ 1: The company name is Affibody Medical AB. The company is a public company (publ).
§ 2: The Company has its registered office in Stockholm. General meetings can also be held in Solna.
§ 4 The share capital shall amount to not less than SEK 50 000 000 and a maximum of SEK 200 000 000.
§ 5: The number of shares shall be not less than 10 000 000, and a maximum of 40 000 000 shares.
Consolidation of shares
It was resolved to conduct a reverse share split, whereby twenty (20) shares will be consolidated into one (1) share in order to achieve an appropriate number of shares. The par value will, as a result of this action, increase from 0.25 per share to SEK 5.00 per share.,
Holders of shares whose ownership is not evenly divisible by 20 will be provided the requisite number of shares (so-called excess shares) so that the holding will be divisible by 20.
The Board is proposed to determine the record date for the reverse split.
For full details on each proposal adopted by the EGM please refer to www.affibody.com.
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daiici-Sankyo, Daewoong and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor AB.
Further information can be found at: www.affibody.com